Ventum Cap Mkts Has Strong Forecast for TSE:MDP Q1 Earnings

Medexus Pharmaceuticals Inc. (TSE:MDPFree Report) – Investment analysts at Ventum Cap Mkts raised their Q1 2026 earnings per share estimates for Medexus Pharmaceuticals in a report issued on Wednesday, January 22nd. Ventum Cap Mkts analyst M. Czmielewski now anticipates that the company will post earnings of ($0.09) per share for the quarter, up from their prior estimate of ($0.10). Ventum Cap Mkts currently has a “Strong-Buy” rating on the stock. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share. Ventum Cap Mkts also issued estimates for Medexus Pharmaceuticals’ Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.01) EPS, Q4 2026 earnings at $0.03 EPS and FY2026 earnings at ($0.12) EPS.

Other equities research analysts also recently issued research reports about the company. Raymond James raised Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 price objective for the company in a report on Wednesday, January 8th. Leede Financial upgraded shares of Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, January 22nd. Stifel Nicolaus boosted their price objective on shares of Medexus Pharmaceuticals from C$4.15 to C$4.50 in a research note on Tuesday, January 14th. Finally, Alliance Global Partners upgraded shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, December 23rd. One investment analyst has rated the stock with a buy rating and five have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Strong Buy” and a consensus price target of C$5.58.

Check Out Our Latest Research Report on Medexus Pharmaceuticals

Medexus Pharmaceuticals Stock Down 6.5 %

MDP stock opened at C$4.60 on Monday. The company has a market cap of C$112.84 million, a price-to-earnings ratio of 92.00 and a beta of 1.96. Medexus Pharmaceuticals has a twelve month low of C$1.47 and a twelve month high of C$5.56. The business has a 50 day moving average price of C$3.30 and a two-hundred day moving average price of C$2.74.

Medexus Pharmaceuticals Company Profile

(Get Free Report)

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.

Featured Articles

Earnings History and Estimates for Medexus Pharmaceuticals (TSE:MDP)

Receive News & Ratings for Medexus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medexus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.